Kiora Pharmaceuticals, Inc.: Kiora's Investigational Treatment for Retinitis Pigmentosa, KIO-301, Demonstrates Visual Function Restoration in Patients Who Are Blind

Encinitas, California--(Newsfile Corp. - April 27, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) presented preliminary results from an ongoing clinical trial showing its investigational drug, KIO-301,

Related Keywords

Kiora ,New South Wales ,Australia ,Adelaide ,South Australia ,Eric Daniels ,Francina Agosti ,Robert Casson ,Brianm Strem ,Twitter ,National Eye Institute ,Association For Research ,California Newsfile Corp ,Kiora Pharmaceuticals ,Linkedin ,Principal Investigator ,Royal Adelaide ,Chief Development Officer ,Photoswitch Molecule ,Retinitis Pigmentosa ,Ocular Presentation ,Rheumatoid Arthritis ,Dihydroorotate Dehydrogenase ,Private Securities Litigation Reform Act ,Annual Report ,Pharmaceuticals ,Investigational ,Treatment ,Retinitis ,Pigmentosa ,Emonstrates ,Visual ,Junction ,Restoration ,Patients ,Blind ,